Geneva, May 18 -- International Clinical Trials Registry received information related to the study (ChiCTR2600124298) titled 'Firmonertinib (160mg) as First-line Therapy for Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR/TP53 Co-Mutation: An Open-Label, Single-Arm, Multicenter Clinical Study' on May 9.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: The Second Affiliated Hospital of Nanjing Medical University

Condition: Non-small cell lung cancer

Recruitment Status: Recruiting

Phase: 2

Date of First Enrollment: 2025-10-29

Target Sample Size: Experimental group:30;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.html?proj=276407

Publishe...